Tommaso Costa

Tommaso Costa

Auto-generated profile, based on publicly available information

Tommaso Costa

Department of Pharmacology, Istituto Superiore di Sanità, Rome, Italy

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1993 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
RLRobert J. Lefkowitz
Robert J. Lefkowitz
SCSusanna Cotecchia
Susanna Cotecchia
PSPhilippe Samama
Philippe Samama
TCTommaso Costa
Tommaso Costa

13 July 2016 in Nature
Verified
Journal Article
Open access
PDF file
DSDean P. Staus
Dean P. Staus
RSRyan T. Strachan
Ryan T. Strachan
AMAashish Manglik
Aashish Manglik
BPBiswaranjan Pani
Biswaranjan Pani
AKAlem W. Kahsai
Alem W. Kahsai
RLRobert J. Lefkowitz
Robert J. Lefkowitz
Stabilization of an active and inactive conformation of the β2-adrenergic receptor by allosteric nanobodies reveals differential ligand-dependent regulation of receptor states to control G-protein-coupled receptor activation. In this manuscript, the authors studied how a positive allosteric nanobody (Nb80) and a newly discovered negative allosteric nanobody (Nb60) alter the structure of the β2-adrenergic receptor (β2AR). Their data support a three-state model for receptor activation in this important G-protein-coupled receptor, rather than a simple inactive–active two-state model. They also find that full agonists primarily stabilize the active Nb80-stabilized receptor state (while having negligible effects on the inactive Nb60-bound state), but partial agonists appear to regulate multiple receptor states to control receptor activation. G-protein-coupled receptors (GPCRs) modulate many physiological processes by transducing a variety of extracellular cues into intracellular responses. Ligand binding to an extracellular orthosteric pocket propagates conformational change to the receptor cytosolic region to promote binding and activation of downstream signalling effectors such as G proteins and β-arrestins. It is well known that different agonists can share the same binding pocket but evoke unique receptor conformations leading to a wide range of downstream responses (‘efficacy’)1. Furthermore, increasing biophysical evidence, primarily using the β2-adrenergic receptor (β2AR) as a model system, supports the existence of multiple active and inactive conformational states2,3,4,5. However, how agonists with varying efficacy modulate these receptor states to initiate cellular responses is not well understood. Here we report stabilization of two distinct β2AR conformations using single domain camelid antibodies (nanobodies)—a previously described positive allosteric nanobody (Nb80)6,7 and a newly identified negative allosteric nanobody (Nb60). We show that Nb60 stabilizes a previously unappreciated low-affinity receptor state which corresponds to one of two inactive receptor conformations as delineated by X-ray crystallography and NMR spectroscopy. We find that the agonist isoprenaline has a 15,000-fold higher affinity for β2AR in the presence of Nb80 compared to the affinity of isoprenaline for β2AR in the presence of Nb60, highlighting the full allosteric range of a GPCR. Assessing the binding of 17 ligands of varying efficacy to the β2AR in the absence and presence of Nb60 or Nb80 reveals large ligand-specific effects that can only be explained using an allosteric model which assumes equilibrium amongst at least three receptor states. Agonists generally exert efficacy by stabilizing the active Nb80-stabilized receptor state (R80). In contrast, for a number of partial agonists, both stabilization of R80 and destabilization of the inactive, Nb60-bound state (R60) contribute to their ability to modulate receptor activation. These data demonstrate that ligands can initiate a wide range of cellular responses by differentially stabilizing multiple receptor states.

1 January 1979 in Nature
Verified
Journal Article
Closed access
TCTommaso Costa
Tommaso Costa
DRDavid Rodbard
David Rodbard
CPCandace B. Pert
Candace B. Pert

4 February 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ASAlexander Scheer
Alexander Scheer
FFFrancesca Fanelli
Francesca Fanelli
TCTommaso Costa
Tommaso Costa
PBPier G. De Benedetti
Pier G. De Benedetti
SCSusanna Cotecchia
Susanna Cotecchia
In this study, a quantitative approach was used to investigate the role of D142, which belongs to the highly conserved E/DRY sequence, in the activation process of the α 1B -adrenergic receptor (α 1B -AR). Experimental and computer-simulated mutagenesis were performed by substituting all possible natural amino acids at the D142 site. The resulting congeneric set of proteins together with the finding that all the receptor mutants show various levels of constitutive (agonist-independent) activity enabled us to quantitatively analyze the relationships between structural/dynamic features and the extent of constitutive activity. Our results suggest that the hydrophobic/hydrophilic character of D142, which could be regulated by protonation/deprotonation of this residue, is an important modulator of the transition between the inactive (R) and active (R*) state of the α 1B -AR. Our study represents an example of quantitative structure-activity relationship analysis of the activation process of a G protein-coupled receptor.

1 May 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RSRyan T. Strachan
Ryan T. Strachan
JSJin-Peng Sun
Jin-Peng Sun
DRDavid H. Rominger
David H. Rominger
JVJonathan D. Violin
Jonathan D. Violin
SASeungkirl Ahn
Seungkirl Ahn
RLRobert J. Lefkowitz
Robert J. Lefkowitz
The concept of "biased agonism" arises from the recognition that the ability of an agonist to induce a receptor-mediated response (i.e. "efficacy") can differ across the multiple signal transduction pathways (e.g. G protein and β-arrestin (βarr)) emanating from a single GPCR. Despite the therapeutic promise of biased agonism, the molecular mechanism(s) whereby biased agonists selectively engage signaling pathways remain elusive. This is due in large part to the challenges associated with quantifying ligand efficacy in cells. To address this, we developed a cell-free approach to directly quantify the transducer-specific molecular efficacies of balanced and biased ligands for the angiotensin II type 1 receptor (AT1R), a prototypic GPCR. Specifically, we defined efficacy in allosteric terms, equating shifts in ligand affinity (i.e. KLo/KHi) at AT1R-Gq and AT1R-βarr2 fusion proteins with their respective molecular efficacies for activating Gq and βarr2. Consistent with ternary complex model predictions, transducer-specific molecular efficacies were strongly correlated with cellular efficacies for activating Gq and βarr2. Subsequent comparisons across transducers revealed that biased AT1R agonists possess biased molecular efficacies that were in strong agreement with the signaling bias observed in cellular assays. These findings not only represent the first measurements of the thermodynamic driving forces underlying differences in ligand efficacy between transducers but also support a molecular mechanism whereby divergent transducer-specific molecular efficacies generate biased agonism at a GPCR.

1 December 2005 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
TCTommaso Costa
Tommaso Costa
SCSusanna Cotecchia
Susanna Cotecchia